Navigation Links
New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice
Date:7/13/2014

INDIANAPOLIS, July 13, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from its non-clinical study in genetically engineered mice examining combination therapy with the murine version of the beta-amyloid antibody N3pG and beta-secretase inhibitor BACE (LY2811376). Data results found that combination therapy was more effective in removing clumps of amyloid-beta protein in the brain – a component that is thought to lead to Alzheimer's disease (AD) – than use of one therapy. These data were presented today at the Alzheimer's Association International Conference 2014 (AAIC 2014) in Copenhagen, Denmark by Ron DeMattos, Ph.D., research fellow in the Neuroscience Division at Eli Lilly and Company. The data was also featured by the AAIC in a research media tips sheet.

"This non-clinical study demonstrates that by simultaneously targeting two different steps in the beta-amyloid disease process, researchers can slow the progression of Alzheimer's disease pathology in genetically engineered mice," said Dr. DeMattos. "These results may have a significant impact on the future of Alzheimer's disease therapies as they support the clinical rationale for using future testing of combination therapy against the a-beta protein in the clinical practice."

Alzheimer's disease, the most common form of dementia, causes progressive decline in memory and other aspects of cognition. A number of new investigational mechanisms for the treatment of Alzheimer's disease are currently in development. One type of investigational mechanism, called beta-secretase inhibitors, aims to block the body's ability to produce beta-amyloid protein, a possible component that leads to Alzheimer's disease. The other type of investigational drug is called a beta-amyloid antibody, which targets the removal of the beta-amyloid protein. Compounds that are thought to work through these mechanisms have been studied in clinical trials on their own; however, most of the trials have not shown significant treatment effects. Therefore, many believe that multiple steps of the beta-amyloid deposition process need to be simultaneously targeted in order to remove significant quantities of the beta-amyloid pathology.

The non-clinical study results showed that when used on their own (as monotherapies), the beta-secretase inhibitor and the N3pG beta-amyloid antibody removed approximately 50 percent of the clumps of amyloid-beta protein, whereas the combination therapy resulted in an even more substantial 86 percent removal. Additionally, combination therapy significantly lowered deposited Aβ1-42 75 percent relative to the time zero controls. Histological analyses indicated that the BACE inhibitor monotherapy resulted in removal of diffuse deposits of beta-amyloid, the antibody monotherapy resulted in removal of cored plaques, and the combination therapy removed both the diffuse deposits and cored plaques. Multiple different types of biochemical analyses confirmed that the combination treatment was superior to the monotherapy treatments. 

Study Methods
Aged PDAPP transgenic mice (17-19 months) were randomized into the following five cohorts: 1) time zero control, 2) large and small molecule compound controls, 3) plaque-specific Aβ antibody (anti-Aβp3-x), 4) BACE inhibitor, and 5) Aβ antibody + BACE inhibitor. The aged mice were treated for four months with either a beta-secretase inhibitor or the N3pG beta-amyloid antibody, or the combination of the two drugs. Effectiveness of the treatments was determined by measuring the amount of beta-amyloid protein remaining in the brains of the mice.

About Alzheimer's Disease
Alzheimer's disease is a fatal illness that causes progressive decline in memory and other aspects of cognition.1 It is the most common form of dementia, accounting for 60 to 80 percent of dementia cases.1 There are currently an estimated 44 million people living with dementia worldwide.2 The number of people affected by dementia is expected to be more than 75 million in 2030 and 135 million in 2050.2   

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels.

P-LLY

Refer to: Stefanie Prodouz, +1 (317) 224-5331, prodouzs@lilly.com

1 Alzheimer's Association. 2014 Alzheimer's Disease Facts and Figures. http://www.alz.org/downloads/facts_figures_2014.pdf. Accessed on June 4, 2014.

2 Alzheimer's Disease International. Policy Brief for Heads of Government: The Global Impact of Dementia 2013 - 2050. http://www.alz.co.uk/research/GlobalImpactDementia2013.pdf. Published December 2013. Accessed on June 4, 2014.

Logo - http://photos.prnewswire.com/prnh/20031219/LLYLOGO


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Newly Published Survey Shows Drug Shortages Still Have Major Impact on Patient Care
2. Salutron, Inc. Showcases Benefits of Heart Rate Measurement in Activity Monitoring at ShowStoppers and CES 2014
3. MedShape DynaNail Shows Successful Outcomes in High-Risk Patients
4. New Peer-Reviewed Study Shows Mixed Results in ACO Medication Readiness To Achieve Quality, Cost Goals
5. Initial Data from Lightlake Therapeutics Joint Clinical Trial with NIDA Shows Nasal Delivery of Naloxone for Opioid Overdose as a Promising Treatment
6. PCMA: CMS Analysis Shows Mail-Service Pharmacies More Affordable Than Drugstores
7. Imaging Shows Long-term Impact of Blast-induced Brain Injuries in Veterans
8. Phase IIb Study of Vanoxerine Shows Strong Safety and Statistically Significant Efficacy Signals for Treatment of Atrial Fibrillation
9. Landmark study of more than 27,000 women shows favorable results of Roches CINtec PLUS cytology test
10. InspireMDs MGuard Stent Shows Lower Mortality Rate in STEMI Patients at Twelve Months Compared to Control Group
11. New Study Shows Promise For First Effective Medicine To Treat Cocaine Dependence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2017)...  Bayer will present the latest research from across its ... (ESMO) 2017 Congress, September 8-12 in Madrid, Spain ... clinical data on Bayer,s marketed portfolio and late-stage compounds as ... "We value the opportunity to ... at ESMO," said Carsten Brunn , Head of Pharmaceuticals, ...
(Date:8/29/2017)... Aug. 29, 2017 ivWatch, LLC, the leading provider of ... announced it has been awarded an Innovative Technology contract from Vizient, ... country. ... to aid in the early detection of peripheral IV infiltration and ... The Innovative Technology contract was ...
(Date:8/28/2017)... -- Hill-Rom Holdings, Inc. (NYSE: HRC), will present at the ... in New York . John Greisch ... present at 11:05 a.m. Eastern Time. The ... A recorded replay will be available one hour after the ... About Hill-Rom Holdings, Inc. ...
Breaking Medicine Technology:
(Date:9/21/2017)... ... , ... SABRE is raising awareness about personal safety with a Chicago Transit ... , The Chicago, Illinois, based self-defense brand has been waiting for an opportunity like ... taking their personal safety into their own hands. , The ads focus on their ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... Report**, http://www.fdanews.com/products/54818-promotional-communication      , In the competitive world of drug and device ... staying in compliance with FDA rules. , The FDA has issued two draft ...
(Date:9/21/2017)... ... September 21, 2017 , ... Demonstrating a ... public health departments have been awarded five-year accreditation status through the Public ... of being served by a PHAB-accredited health department now extend to more ...
(Date:9/21/2017)... ... ... In addition to sticking with the new years goal ... use natural alternatives for all house cleaning products, disinfectants, respiratory relief, and much ... new line of essential oils, are all 100% organic and natural. , Combine ...
(Date:9/21/2017)... ... September 21, 2017 , ... The New England Center for Children® (NECC®), a ... of Yie-Hsin Hung to the Board of Directors. , “The New England Center ... Hung is an invaluable addition to our team,” said Vincent Strully, Jr., President and ...
Breaking Medicine News(10 mins):